Prelude Therapeutics PRLD Stock
Prelude Therapeutics Price Chart
Prelude Therapeutics PRLD Financial and Trading Overview
| Prelude Therapeutics stock price | 3.63 USD |
| Previous Close | 3.6 USD |
| Open | 3.63 USD |
| Bid | 2.63 USD x 200 |
| Ask | 4.39 USD x 200 |
| Day's Range | 3.41 - 3.69 USD |
| 52 Week Range | 1.17 - 6.83 USD |
| Volume | 288.58K USD |
| Avg. Volume | 520.4K USD |
| Market Cap | 289.11M USD |
| Beta (5Y Monthly) | 0.962 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.2 USD |
PRLD Valuation Measures
| Enterprise Value | 236.67M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.25765 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.892992 |
| Price/Book (mrq) | 2.7944572 |
| Enterprise Value/Revenue | 10.555 |
| Enterprise Value/EBITDA | -3.669 |
Trading Information
Prelude Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.962 |
| 52-Week Change | 122.22% |
| S&P500 52-Week Change | 12.83% |
| 52 Week High | 6.83 USD |
| 52 Week Low | 1.17 USD |
| 50-Day Moving Average | 4.68 USD |
| 200-Day Moving Average | 3.97 USD |
PRLD Share Statistics
| Avg. Volume (3 month) | 520.4K USD |
| Avg. Daily Volume (10-Days) | 546.32K USD |
| Shares Outstanding | 64.92M |
| Float | 22.06M |
| Short Ratio | 8.95 |
| % Held by Insiders | 13.76% |
| % Held by Institutions | 76.41% |
| Shares Short | 4.58M |
| Short % of Float | 18.07% |
| Short % of Shares Outstanding | 5.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -269.74% |
| Operating Margin (ttm) | -270.93% |
| Gross Margin | 100.00% |
| EBITDA Margin | -287.68% |
Management Effectiveness
| Return on Assets (ttm) | -27.15% |
| Return on Equity (ttm) | -57.72% |
Income Statement
| Revenue (ttm) | 22.42M USD |
| Revenue Per Share (ttm) | 0.27 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 22.42M USD |
| EBITDA | -64510000 USD |
| Net Income Avi to Common (ttm) | -60488000 USD |
| Diluted EPS (ttm) | -0.73 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 151.76M USD |
| Total Cash Per Share (mrq) | 1.47 USD |
| Total Debt (mrq) | 17.65M USD |
| Total Debt/Equity (mrq) | 13.2 USD |
| Current Ratio (mrq) | 4.072 |
| Book Value Per Share (mrq) | 1.299 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33255000 USD |
| Levered Free Cash Flow (ttm) | -13844625 USD |
Profile of Prelude Therapeutics
| Country | United States |
| State | DE |
| City | Wilmington |
| Address | 175 Innovation Boulevard |
| ZIP | 19805 |
| Phone | 302 467 1280 |
| Website | https://preludetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 79 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Q&A For Prelude Therapeutics Stock
What is a current PRLD stock price?
Prelude Therapeutics PRLD stock price today per share is 3.63 USD.
How to purchase Prelude Therapeutics stock?
You can buy PRLD shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Prelude Therapeutics?
The stock symbol or ticker of Prelude Therapeutics is PRLD.
Which industry does the Prelude Therapeutics company belong to?
The Prelude Therapeutics industry is Biotechnology.
How many shares does Prelude Therapeutics have in circulation?
The max supply of Prelude Therapeutics shares is 79.65M.
What is Prelude Therapeutics Price to Earnings Ratio (PE Ratio)?
Prelude Therapeutics PE Ratio is now.
What was Prelude Therapeutics earnings per share over the trailing 12 months (TTM)?
Prelude Therapeutics EPS is -0.73 USD over the trailing 12 months.
Which sector does the Prelude Therapeutics company belong to?
The Prelude Therapeutics sector is Healthcare.
Prelude Therapeutics PRLD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25955.34 USD — |
-0.21
|
5.73B USD — | 25866.15 USD — | 26111.62 USD — | — - | 5.73B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12785.11 USD — |
-0.19
|
— — | 12740.9 USD — | 12862.43 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6992.35 USD — |
-1.13
|
— — | 6939.19 USD — | 7028.81 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1327.92 USD — |
-0.97
|
— — | 1320.94 USD — | 1335.06 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
